The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.

The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

NEW YORK – InformedDNA on Wednesday said it has acquired Coriell Life Sciences, a pharmacogenomics and clinical-decision support company. St. Petersburg, Florida-based InformedDNA, which provides ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.